TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05915416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Abuse and Neglect Prevention Program
Description: The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
Study: NCT06087237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400 mg pentoxifylline oral tablets three times per day starting from the day before surgery till two weeks after the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets three times per day starting from the day before surgery till two weeks after the surgery.
Study: NCT06364449

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05432414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
Study: NCT06382727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EN will be continued up to extubation (EN will not be withheld prior to extubation)
Description: As per the arm/group descriptions.
Study: NCT05497804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study: NCT06007352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 L of NaCl irrigation typically used for ureteroscopy surgery
Study: NCT06582849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard assistance
Description: Standard assistance includes all community and institutional resources currently available for which the participant qualifies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced assistance
Description: Enhanced assistance includes gift cards and checks to support food, housing, utilities, transportation, pharmacy, and other non-medical costs
Study: NCT04617522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study: NCT04466527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Intervention
Description: Subjects with undergo laser exposure of their active acne vulgaris.
Study: NCT04762277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab - solution for infusion
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching spesolimab - solution for infusion
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab- solution for injection
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to spesolimab- solution for injection
Description: Solution for injection
Study: NCT05897710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual World-Based Cardiac Rehabilitation (VWCR)
Description: 12-week virtual world technology-based program via Second Life platform. Weekly virtual visits with nurse coach and exercise physiologist, weekly education sessions, and social support group discussions within the virtual world environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center-Based Cardiac Rehabilitation (CBCR)
Description: Traditional 12-week in-person cardiac rehabilitation program; standard of care at participant's cardiac rehabilitation facility
Study: NCT06560879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei
Description: Lacticaseibacillus casei is a species of Gram-positive anaerobic bacteria found in the intestine and mouth of humans. This lactic acid-producing bacterium is used in the dairy industry in the production of probiotic foods.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: A live form of a bacterium that makes lactic acid (a substance derived from milk sugars and also made by the body). Lactobacillus rhamnosus GG is given to help with digestion and normal bowel function. In addition, it may help maintain a healthy gastrointestinal tract. It is being studied for the prevention of infections in patients who received donor stem cell transplants and for other conditions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum
Description: B. bifidum is an essential bacteria found in the human intestine. When it is low or absent all together in the human intestine, it is an indication of being in an unhealthy state. Intestinal flora can be improved if someone takes oral B. bifidum. Also, oral B. bifidum is used for other things such as therapy for enteric and hepatic disorders, for activating the immune response, and for preventing some cancers
Study: NCT04896736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
Study: NCT06560879

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production.The most common form is used in vitamin supplements or tablets
Study: NCT06181669

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathogen and Host Directed testing
Description: This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository.
Study: NCT01085721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine, pseudoephedrine, guaifenesin
Description: 5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine
Description: 5 mL (2 mg dexchlorpheniramine) qid for 5 days
Study: NCT05290727

Intervention type: OTHER
Group type: OTHER
Intervention: Aquoral Lipo (Esteve)
Description: 15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products

Intervention type: OTHER
Group type: OTHER
Intervention: Aquoral Lipo (Esteve)
Description: 15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products

Intervention type: OTHER
Group type: OTHER
Intervention: Hyabak (Thea)
Description: 15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products

Intervention type: OTHER
Group type: OTHER
Intervention: Hyabak (Thea)
Description: 15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
Study: NCT05875311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: The system consists of the following elements:~Professional website at the ambulatory centre, which allows:~To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients

Intervention type: OTHER
Group type: OTHER
Intervention: control follow-up
Description: Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles
Study: NCT05676346

Intervention type: GENETIC
Intervention: LUTS
Description: Patients included in this group are subjects with lower urinary tracto symptoms. An oral mucosa swab will be used to extract a genetic specimen
Study: NCT05484661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (\~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BCAA
Description: Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (\~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
Study: NCT05858853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Serum Albumin
Description: The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Serum Albumin
Description: The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin
Description: Control drug (human blood albumin injection) 10 g/ day for 14 days
Study: NCT05497804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV/PO
Study: NCT04149119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attractive Target Sugar Baits (ATSB)
Description: Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
Study: NCT06440226

Intervention type: BEHAVIORAL
Intervention: Eye Movement Technique
Description: Participants were instructed to move their eyes as much as possible with their eyes closed just before falling asleep. This technique aimed to mimic the Rapid Eye Movement (REM) sleep phase, which is often associated with more vivid and memorable dreams.

Intervention type: BEHAVIORAL
Intervention: Memory Recall of Previous Night's Thoughts
Description: Another intervention involved asking participants to recall and think about their thoughts or events from the previous night before going to sleep. This method engaged cognitive processes related to memory and reflection, potentially setting the stage for increased awareness during sleep.

Intervention type: BEHAVIORAL
Intervention: Recall of Previous Lucid Dreams
Description: Participants were also asked to recall their lucid dreams from previous nights. This intervention seemed to activate memory and awareness related to dreaming, which significantly increased the likelihood of experiencing lucid dreams the following night.
Study: NCT05497804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study: NCT06583018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Mindfulness-based Group Sessions
Description: The 3-hour group-based session in week 1 focuses on experiential mindfulness practices, and a booster session in week 5 further consolidates these mindfulness techniques, reinforces mindful, healthy lifestyle, and provides peer support. Participants will enhance their self-awareness of positive, neutral, and negative body sensations, feelings, and thoughts while engaging in healthy behaviors, particularly physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Interventions (EMI)
Description: Participants will receive personalized instant messages with chat-based support throughout the 8-week intervention period. The message content is guided by existing international lifestyle modification guidelines and the Integrated Body-Mind-Spirit Model. The pre-set frequency of regular message delivery is five times per week. The schedule of message delivery will be personalized according to the participants' on-going needs/preferences over the intervention period. Chat-based support will be provided by trained research assistants, who will utilize motivational interviewing techniques to enhance participant compliance and effectiveness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Lifestyle Education Session
Description: A 3-hour group-based session in week 1 focused on general education on lifestyle modification based on the HEARTS technical package as recommended by the WHO, and will only receive reminder messages for the two assessment follow-ups. No chat-based support will be provided.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Monitoring
Description: All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitoring
Description: All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life.
Study: NCT06581198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel Regimen 1
Description: single infusion of rapcabtagene autoleucel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel Regimen 2
Description: single infusion of rapcabtagene autoleucel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The treatment regimen must be in line with KDIGO guidelines for treatment of class III/IV LN.
Study: NCT06063499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program for Addictions
Description: The Healthy Minds Program for Addictions is a 6-week, hybrid version of the original Healthy Minds Program (HMP), in which all lessons are adapted from the original lessons available in the app and delivered exclusively in person over weekly group sessions. The HMP has \>100 guided audio practices that address 4 constituents of wellbeing: awareness, connection, insight, and purpose. Study participants will have access to specific practices from the HMP that are particularly relevant to the needs of populations with substance use disorders and trauma.
Study: NCT04903470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropin
Description: Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
Study: NCT05490290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
Study: NCT06310187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Oxidant Unflavored Little Cigar - Group A
Description: Subjects will be provided with high oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant unflavored little cigar to use for outcome measure data collection in the lab)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Oxidant Unflavored Little Cigar - Group B
Description: Subjects will be provided with low oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant unflavored little cigar to use for outcome measure data collection in the lab)
Study: NCT05858853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin
Description: Control drug (human blood albumin injection) 20 g/ day for 7 days
Study: NCT05850910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supine practice group
Description: The practitioner's arm was placed in the mid-thoracic region from the opposite side of the individual's torso in the form of a half fist. In this position, the SPs coincide with the space in the middle of the half fist, while the TPs coincide with the fingertips and the thenar region. With the practitioner's other hand supporting the patient's elbows, a high-speed-low-amplitude thrust is applied from front to back.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone application group
Description: the practitioner positions the hypothenar part of his hands above the TPs in the mid-thoracic segment. From this point, a high-velocity-low-amplitude thrust is applied from the back to the front.
Study: NCT06310187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Oxidant Flavored Little Cigar - Group C
Description: Subjects will be provided with high oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant flavored little cigar to use for outcome measure data collection in the lab)
Study: NCT06168630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage
Description: It consists of patients who will receive manual lymph drainage everyday for 5 days. The subject's position will be supine with their knees bent. Every session will be of 45 minutes. Manual lymph drainage will with abdominal lymph drainage, after which central lymph stimulation will be performed. Then, by stimulating the bilateral axillary lymph nodes, the flow of fluid over the right and left breasts will be directed toward the axillary lymph nodes. While the patients in the prone position, bilateral axillary lymph nodes will be stimulated, and each manual lymph drainage will be performed from the dorsum to the axillary lymph node .

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The other group will receive massage for 20 minutes every day for 5 days from first day of treatment. Massage will be done using the index and middle fingers in a spiral motion towards the nipples.
Study: NCT06310187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Oxidant Flavored Little Cigar - Group D
Description: Subjects will be provided with low oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant flavored little cigar to use for outcome measure data collection in the lab)

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Cigarette - Group E
Description: Subjects will use one of their own cigarettes in the collection of outcome measure data in the lab.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unlit Little Cigar - Group F
Description: Subjects will be provided with an unlit little cigars to use for outcome measure data collection in the lab. This will be the control group for outcome measure data.
Study: NCT05059327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basimglurant with crossover to Placebo
Description: Basimglurant with crossover to Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with crossover to Basimglurant
Description: Placebo with crossover to Basimglurant